March 2010
Pharmaceutical Representative;Mar2010, Vol. 40 Issue 3, p10
The article offers updates related to clinical trials in the pharmaceutical industry. The Merck Serono SA's 96-week CLARITY trial using Claribine tablets has been published at the New England Journal of Medicine. Lexicon Pharmaceuticals Inc. has obtained good results for its Phase II trial of the LX4211 drug for diabetics. The Phase II study of Pfizer Inc.'s Tanezumab has been presented at the American Academy of Pain Medicine's 26th annual conference.


Related Articles

  • Research Update.  // PharmaWatch: Biotechnology;Jun2009, Vol. 8 Issue 6, p6 

    The article offers world news briefs related to pharmaceutical industry in 2009. A Phase III trial to evaluate the efficacy of safinamide as add-on therapy for Parkinson's disease was initiated by Merck Serono SA and Newron Pharmaceuticals SpA. A Phase III clinical trial of the investigational...

  • Stimuvax Trials on Hold Due to Encephalitis Case.  // Bioworld Week;3/29/2010, Vol. 18 Issue 13, p3 

    The article reports on the move of Merck Serono SA, a unit of Merck KGaA, to suspend clinical Phase III trials of Stimuvax in non-small-cell lung cancer (NSCLC) and breast cancer due to inflammation of the study patient's brain.

  • CLINIC ROUNDUP.  // BioWorld Today;1/26/2009, Vol. 20 Issue 15, p5 

    This section offers news briefs on the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of Alnylam Pharmaceuticals Inc. to test ALN-VSP, an RNAi therapeutic, as treatment for liver cancers. The clinical trial of Merck...

  • The Industry.  // Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p7 

    The article offers world news briefs involving pharmaceutical companies. It cites that GlaxoSmithKline is facing legal charges for its diabetes drug Avandia, alongside sales practices of its product in the U.S. It notes that Merck Serono SA entered into an agreement with Domain Therapeutics SA...

  • European Conference of Clinical Oncology.  // BioWorld Today;9/26/2007, Vol. 18 Issue 187, p4 

    The article reveals the results of several Erbitux (cetuximab) studies by Merck Serono International SA, including a Phase III trial showing the drug's safety when added to a combination of capecitabine, oxaliplatin and bevacizumab. Data showed an increase of progression-free survival in the...

  • Merck Serono Takes Japanese Option To R763 From Rigel. Morrison, Trista // BioWorld Today;11/15/2007, Vol. 18 Issue 223, p1 

    The article reports on the decision of Merck Serono SA to exercise its option to take licensing rights for the Aurora kinase inhibitors from Rigel Pharmaceuticals Inc. A Phase I cancer trials are being conducted by Serono with the lead drug in the program. The drug is designed to inhibit Aurora...

  • Merck Serono reports encouraging results from colorectal cancer study.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p8 

    The article reports on the final results of the Crystal colorectal cancer study conducted by Merck Serono SA, a pharmaceutical company, which reveals that Erbitux provided an improvement in overall survival when added to the standard firstline Folfiri chemotherapy regimen for metastatic...

  • Update.  // Medical Marketing & Media;Apr2013, Vol. 48 Issue 4, p23 

    The article offers news briefs related to the pharmaceutical industry including the updated iQ.mercury e-detailing platform of GSW, the AgileM mobile analytic platform launched by Trinity Pharma, and the Ondaco Sarl information technology consulting services company launched by Merck Serono SA.

  • Pharma: Other News To Note.  // BioWorld Today;8/10/2012, Vol. 23 Issue 155, p7 

    This section offers news briefs on the U.S. pharmaceutical industry as of August 2012, which includes the collaboration of Bristol-Myers Squibb Co. and AstraZeneca plc, the labor dispute involving Merck Serono SA and market approval of Vanda Pharmaceuticals Inc.'s antischizophrenic drug Fanapt.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics